Latest Profitability News

Austco Healthcare has reported a robust first half of 2026, with revenue surging 31% and EBITDA jumping 60%, underpinned by solid contract backlog and debt-free balance sheet.

IGNITE Limited reports a challenging first half of FY26 with an 18% revenue decline and a halving of statutory profit, yet maintains a fully franked interim dividend amid a strategic business closure.

Bell Financial Group delivered a robust 17.1% rise in net profit after tax to $36 million for 2025, driven by strong growth in its Platforms division and a rebound in market activity. The company declared a fully franked final dividend of 6.5 cents per share, signalling confidence as it prepares to launch a new wealth management platform in 2026.

Rhythm Biosciences reported a $2.26 million half-year loss as it advances ColoSTAT into commercialisation and expands geneType partnerships, signalling a pivotal phase for the ASX-listed medical diagnostics company.

Knosys Limited reported a 4.6% revenue increase to $5.07 million for the half-year ending December 2025, driven by stronger licence and project fees. However, the company’s net loss widened significantly to $1.53 million, reflecting heavy investment in its next-generation Libero X library management system.

BKI Investment Company has finalised its on-market share purchases to satisfy its Dividend Reinvestment Plan obligations, setting the DRP price at $1.74 ahead of the 2026 interim dividend payment.

Sports Entertainment Group Limited reported a robust half-year ending December 2025, with revenues climbing 28% and underlying EBITDA soaring 78%, driven by strong media and complementary services growth. The company also finalised its Perth Wildcats divestment, boosting cash reserves.

IDT Australia reports a robust 20.3% increase in core revenue and a dramatic narrowing of EBITDA losses, signalling early success from its strategic realignment under new leadership.

IDT Australia Limited has reported a significant narrowing of its half-year loss to $1.3 million, driven by stable revenues and operational efficiencies. The pharmaceutical manufacturer highlights growth in key segments despite some timing setbacks.

Solvar Limited reported a 5.8% rise in half-year NPAT to $20 million, driven by the sale of its New Zealand written-off loan book and expanded debt facilities. The company also announced a special dividend and outlined growth plans in commercial lending.

Solvar Limited reported a 5.8% rise in net profit for the half year ending December 2025, driven by strategic asset sales and expanded funding facilities. The company declared both interim and special dividends, signalling confidence despite ongoing regulatory challenges.

Servcorp has reported a robust first half for FY2026, with underlying profit soaring 34% and a strong dividend declared, signalling sustained momentum despite economic uncertainties.